The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure

被引：0
|
作者：
Tomoyuki Otsuka
Yukinao Sakai
Dai Ohno
Tsuneo Murasawa
Naoki Sato
Shuichi Tsuruoka
机构：
[1] Nippon Medical School Musashikosugi Hospital,Division of Nephrology, Department of Internal Medicine
[2] Nippon Medical School Musashikosugi Hospital,Division of Cardiology, Department of Internal Medicine
[3] Graduate School of Medicine,Division of Nephrology, Department of Internal Medicine
[4] Nippon Medical School,undefined
来源：
Clinical and Experimental Nephrology | 2013年 / 17卷
关键词：
Tolvaptan; Chronic kidney disease; Diuretic; Congestive heart failure; Renoprotection;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：834 / 838
页数：4
相关论文
共 50 条
  • [41] Tolvaptan for the treatment of hyponatremia and congestive heart failure
    Orlandi, Cesare
    Zimmer, Christopher A.
    Gheorghiade, Mihai
    [J]. FUTURE CARDIOLOGY, 2006, 2 (06) : 627 - 634
  • [42] Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial
    Komiya, Shiro
    Katsumata, Mari
    Ozawa, Moe
    Haze, Tatsuya
    Kawano, Rina
    Ohki, Yuki
    Suzuki, Shota
    Kobayashi, Yusuke
    Fujiwara, Akira
    Saka, Sanae
    Tamura, Kouichi
    Hirawa, Nobuhito
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2022, 26 (09) : 851 - 858
  • [43] Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure
    Ikeda, Shuntaro
    Ohshima, Kiyotaka
    Miyazaki, Shigehiro
    Kadota, Hisaki
    Shimizu, Hideaki
    Ogimoto, Akiyoshi
    Hamada, Mareomi
    [J]. ESC HEART FAILURE, 2017, 4 (04): : 614 - 622
  • [44] Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial
    Shiro Komiya
    Mari Katsumata
    Moe Ozawa
    Tatsuya Haze
    Rina Kawano
    Yuki Ohki
    Shota Suzuki
    Yusuke Kobayashi
    Akira Fujiwara
    Sanae Saka
    Kouichi Tamura
    Nobuhito Hirawa
    [J]. Clinical and Experimental Nephrology, 2022, 26 : 851 - 858
  • [45] Chronic kidney disease and heart failure: is tolvaptan a safe option to treat refractory hyponatremia?
    Salterain Gonzalez, N.
    Esteban Fernandez, A.
    Lavilla Royo, F. J.
    Gavira Gomez, J. J.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 356 - 356
  • [46] Heart Failure in Patients with Chronic Kidney Disease
    Xanthopoulos, Andrew
    Papamichail, Adamantia
    Briasoulis, Alexandros
    Loritis, Konstantinos
    Bourazana, Angeliki
    Magouliotis, Dimitrios E.
    Sarafidis, Pantelis
    Stefanidis, Ioannis
    Skoularigis, John
    Triposkiadis, Filippos
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (18)
  • [47] THE EFFICACY AND SAFETY OF TOLVAPTAN ON TREATING CONGESTIVE HEART FAILURE PATIENTS WITH HYPONATREMIA
    Li Ling
    Zhu Wen-ling
    Bai Hua
    [J]. HEART, 2011, 97
  • [48] A Study on the Long-Term Administration of Tolvaptan to Treat Patients with Heart Failure and Chronic Kidney Disease (CKD)
    Mizuhara, Akihiro
    Aoki, Hiromi
    [J]. JOURNAL OF CARDIAC FAILURE, 2016, 22 (09) : S214 - S214
  • [49] THE EFFICACY AND SAFETY OF TOLVAPTAN ON TREATING CONGESTIVE HEART FAILURE PATIENTS WITH HYPONATREMIA
    Li Ling
    Zhu Wenling
    Bai Hua
    [J]. HEART, 2011, 97
  • [50] Good response to tolvaptan shortens hospitalization in patients with congestive heart failure
    Kogure, Tomohito
    Jujo, Kentaro
    Hamada, Kazuyuki
    Saito, Katsumi
    Hagiwara, Nobuhisa
    [J]. HEART AND VESSELS, 2018, 33 (04) : 374 - 383
12345